| Group |
No |
Serum β2-M (mg/L,) (mean ± SD) |
P |
positive rate (%) |
P |
| Controls |
1002 |
0.99 ± 4.47 |
|
7.88 |
|
| Female benign tumor |
141 |
1.19 ± 2.55 |
＞0.05 |
20.00 |
<0.05 |
| Female breast Ca. |
201 |
2.05 ± 4.81 |
< 0.05 |
30.84 |
<0.05 |
| Female breast Ca, |
|
|
|
|
|
| ages: |
|
|
|
|
|
| ＜40years |
46 |
2.51 ± 6.64 |
|
39.13 |
|
| 40-60years |
127 |
2.15 ± 4.47 |
＞0.05 |
28.34 |
＞0.05 |
| ＞60years |
19 |
0.84 ± 1.75 |
＞0.05 |
7.14 |
< 0.01 |
| cilinical stages |
|
|
|
|
|
| Ⅰ |
14 |
1.77 ± 2.48 |
|
28.57 |
|
| Ⅱ |
116 |
2.50 ± 3.61 |
＞0.05 |
34.48 |
＞0.05 |
| Ⅲ |
24 |
2.18 ± 4.15 |
＞0.05 |
33.33 |
＞0.05 |
| Ⅳ |
14 |
0.74 ± 1.85 |
＞0.05 |
28.57 |
＞0.05 |
| Benign tumor |
243 |
0.68 ± 2.20 |
＞0.05 |
7.81 |
＞0.05 |
| Thyroid Ca. |
95 |
2.84 ± 4.56 |
<0.05 |
34.73 |
<0.01 |
| Thyroid Ca.: |
|
|
|
|
|
| Male: |
26 |
1.71 ± 2.88 |
|
23.07 |
|
| female: |
69 |
3.26 ± 5.00 |
＞0.05 |
36.23 |
＞0.05 |
| ages: |
|
|
|
|
|
| ＜40years |
31 |
2.04 ± 4.35 |
|
22.58 |
|
| 40-60years |
45 |
3.66 ± 4.96 |
＞0.05 |
46.67 |
<0.05 |
| ＞60years |
19 |
2.17 ± 3.71 |
＞0.05 |
26.31 |
＞0.05 |
| cilinical stages |
|
|
|
|
|
| Ⅰ |
28 |
2.07 ± 4.18 |
|
28.57 |
|
| Ⅱ- Ⅲ |
18 |
2.15 ± 1.674.95 |
＞0.05 |
33.33 |
＞0.05 |
| Ⅳ |
20 |
0.23 ± 1.35 |
< 0.01 |
0 |
<0.01 |
| Cell types; |
|
|
|
|
|
| Follicular- -thyroid adenoma |
42 |
2.07 ± 3.75 |
|
19.07 |
|
|
Papillary-thyroid adenoma |
18 |
2.71 ± 4.25 |
＞0.05 |
44.44 |
<0.05 |
|
